Lankenau Heart Institute
Welcome,         Profile    Billing    Logout  
 0 Trials 
3 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Spuhler, Rose
NCT05646381: A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

Recruiting
2
502
Europe, Canada, US, RoW
Pelacarsen (TQJ230) 80mg, TQJ230, Matching placebo, Placebo
Novartis Pharmaceuticals
Aortic Stenosis
03/30
03/30
NCT06212193: Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS)

Recruiting
N/A
15
Europe, US
Trillium™
Innoventric LTD, Innoventric Inc.
Tricuspid Regurgitation, Tricuspid Regurgitation Functional
08/25
08/30
CATALYST, NCT04226547: Amplatzer Amulet LAAO Vs. NOAC

Recruiting
N/A
2650
Europe, Canada, Japan, US, RoW
Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder), Amplatzer Amulet LAA Occluder, Non-Vitamin K Oral Antagonists, NOAC
Abbott Medical Devices
Atrial Fibrillation, Stroke, Bleeding
08/27
08/30
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Spuhler, Rose
NCT05646381: A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

Recruiting
2
502
Europe, Canada, US, RoW
Pelacarsen (TQJ230) 80mg, TQJ230, Matching placebo, Placebo
Novartis Pharmaceuticals
Aortic Stenosis
03/30
03/30
NCT06212193: Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS)

Recruiting
N/A
15
Europe, US
Trillium™
Innoventric LTD, Innoventric Inc.
Tricuspid Regurgitation, Tricuspid Regurgitation Functional
08/25
08/30
CATALYST, NCT04226547: Amplatzer Amulet LAAO Vs. NOAC

Recruiting
N/A
2650
Europe, Canada, Japan, US, RoW
Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder), Amplatzer Amulet LAA Occluder, Non-Vitamin K Oral Antagonists, NOAC
Abbott Medical Devices
Atrial Fibrillation, Stroke, Bleeding
08/27
08/30

Download Options